Heart failure that won’t respond to treatment: Could it be ATTR-CM?
Fact-checked by Transthyretin amyloid cardiomyopathy (ATTR-CM) remains a frequently underdiagnosed cause of heart failure, especially within the elderly population.
This condition falls under the category of cardiac amyloidosis. These diseases occur when abnormal proteins form clumps, creating amyloid deposits in heart tissue. In a patient with ATTR-CM, the transthyretin protein loses stability due to genetic mutations or age-related changes. As these toxic deposits accumulate, they progressively weaken the heart’s ability to pump, potentially resulting in heart failure.
Early detection remains a significant challenge. Because ATTR-CM heart failure mirrors the symptoms of more common cardiovascular issues, many patients face a long road of misdiagnosis before finding the right answers.
Why ATTR-CM can look like other heart conditions
While ATTR-CM and various forms of cardiac amyloidosis frequently cause heart failure, several other medical conditions produce similar changes in heart function and symptoms. Distinguishing among these triggers is a critical step toward an accurate ATTR-CM diagnosis.
The diagnostic process can become more complicated when patients have multiple heart conditions. These coexisting conditions can effectively hide the signs of amyloidosis, making it much harder for clinicians to spot the underlying protein deposits. Identifying the true source of the problem requires a careful, investigative approach to ensure the amyloidosis doesn’t remain masked by more common cardiac problems.
When standard heart failure treatment isn’t working
When a patient experiences treatment-resistant heart failure, the lack of progress may signal that ATTR-CM is the actual root cause. This specific condition alters the heart’s structure in ways that standard cardiac protocols may not always address.
Standard heart medications often prove ineffective or even cause complications for those living with ATTR-CM. These issues arise because the heart’s stiffened walls respond differently to drugs than those of a heart enlarged by more common conditions. Depending on the specific medication’s mechanism, a treatment designed to help a typical patient might fail to improve, or even worsen, the symptoms of someone with amyloid deposits.
| Medications | Effects | Problems in ATTR-CM |
|---|---|---|
| Angiotensin II receptor blockers, angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors | Lower blood pressure | Risk of orthostatic hypotension (sudden drop in blood pressure when standing up) |
| Beta blockers | Lower heart rate | Can further reduce cardiac output |
| Digoxin | Strengthen heart contractions | Can interact with amyloid deposits, potentially causing toxicity |
Given the clear link between treatment-resistant heart failure and amyloidosis, a lack of improvement on standard medications often serves as a red flag for clinicians. When these standard therapies fail to provide relief, patients may need specialized diagnostic testing to detect amyloid deposits in the heart.
These tests allow doctors to look beyond surface-level symptoms and examine the heart tissue’s physical composition. Identifying these protein deposits early can shift the treatment strategy away from ineffective standard protocols and toward a plan that specifically addresses the underlying amyloidosis.
Red flags that may point to ATTR-CM
Beyond a poor response to standard medications, several “red flag” symptoms can point toward an ATTR-CM diagnosis.
Key non-cardiac signs include:
- carpal tunnel syndrome: Pressure on the wrist nerves causing pain, numbness, or weakness in the hands and forearms.
- lumbar spinal stenosis: Narrowing of the spinal canal that leads to lower back pain and numbness.
- peripheral neuropathy: Nerve damage resulting in tingling or abnormal sensations, most frequently in the hands and feet.
Clinicians also look for specific physical changes during an echocardiogram. For instance:
- left ventricular hypertrophy: thickening of the walls of the left ventricle, the heart’s lower left chamber that pumps blood to the rest of the body
- heart failure with preserved ejection fraction (HFpEF): where the heart struggles to relax between beats despite pumping a normal amount of blood.
While high blood pressure typically causes these relaxation issues, doctors often suspect amyloidosis in people with HFpEF if the patient maintains a normal or low blood pressure.
How doctors test for ATTR-CM
To investigate whether unexplained heart failure stems from ATTR-CM, medical teams typically utilize a series of diagnostic tests. Initial suspicion often arises from routine, minimally invasive tests such as:
- echocardiogram (echo): This ultrasound exam monitors the heart’s structure and function.
- electrocardiogram (ECG): This test tracks the heart’s electrical activity to look for specific irregularities.
If these initial results suggest amyloidosis, doctors move toward more specialized procedures to confirm the presence of protein deposits, including:
- blood and urine tests: These help rule out other potential causes of heart failure or different types of amyloidosis.
- cardiac MRI: This scan produces detailed images that often visualize amyloid deposits within the heart walls.
- PYP scan: This specialized imaging technique is highly effective at detecting transthyretin amyloid deposits specifically.
- cardiac biopsy: This remains the definitive method for confirmation, as a small tissue sample from the heart is analyzed directly for amyloid.
Together, these diagnostic tools help clinicians move from general symptoms to a confirmed diagnosis, ensuring patients receive a treatment plan tailored to their specific condition.
Why diagnosis is often delayed
Several factors contribute to a missed ATTR-CM diagnosis, ranging from the condition’s ability to mimic other heart problems to a general lack of awareness among some medical professionals. Because the symptoms mirror more common cardiovascular issues, identifying the true cause requires a high level of clinical suspicion.
Research highlights the scale of this challenge, indicating that up to 57% of people with ATTR-CM initially receive a diagnosis for a different heart condition. This confusion often forces patients to consult multiple healthcare specialists over several years before finding the right answer. Reducing these delays is vital, as early detection enables better disease management and a faster start on the right therapy.
Questions to ask if your heart failure is not improving
When medications fail to relieve symptoms, patients should feel empowered to discuss the possibility of ATTR-CM with their medical team.
Consider asking your doctor these specific questions:
- Do I have other red flags that point toward ATTR-CM?
- Which follow-up tests can definitively confirm or rule out the condition?
- If medications are causing unwanted side effects, why might this be, and are there better alternatives for my specific situation?
Maintaining an open dialogue helps ensure that no symptom is overlooked. By working closely together, patients and providers can streamline the journey toward the right treatment, potentially identifying amyloidosis as the cause of heart failure much sooner.
Amyloidosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
